These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32119186)

  • 1. Which person with diabetes should receive cardioprotective glucose-lowering medicines?
    Bloomgarden ZT
    J Diabetes; 2020 May; 12(5):352-353. PubMed ID: 32119186
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
    Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
    Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
    Nargesi AA; Jeyashanmugaraja GP; Desai N; Lipska K; Krumholz H; Khera R
    J Am Heart Assoc; 2021 Jul; 10(13):e021084. PubMed ID: 33998258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.
    Ahmed HM; Khraishah H; Cho L
    Eur Heart J; 2018 Jul; 39(25):2368-2375. PubMed ID: 29236983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
    Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
    J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes?
    Khunti K; Seidu S; Davies MJ
    Diabetes Obes Metab; 2019 Feb; 21(2):207-209. PubMed ID: 30178516
    [No Abstract]   [Full Text] [Related]  

  • 8. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
    Bailey CJ
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
    Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
    Kalyani RR
    N Engl J Med; 2021 Apr; 384(13):1248-1260. PubMed ID: 33789013
    [No Abstract]   [Full Text] [Related]  

  • 13. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes medications and cardiovascular disease: at long last progress.
    Lupsa BC; Inzucchi SE
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
    Hocher B; Tsuprykov O
    Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
    [No Abstract]   [Full Text] [Related]  

  • 16. Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.
    Kosiborod M
    J Diabetes Complications; 2017 Feb; 31(2):517-519. PubMed ID: 27839923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study.
    van Dalem J; Brouwers MCGJ; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Driessen JHM
    Diabetes Res Clin Pract; 2021 Jun; 176():108828. PubMed ID: 33894280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.
    Vaduganathan M; Patel RB; Singh A; McCarthy CP; Qamar A; Januzzi JL; Scirica BM; Butler J; Cannon CP; Bhatt DL
    J Am Coll Cardiol; 2019 Apr; 73(12):1596-1598. PubMed ID: 30922481
    [No Abstract]   [Full Text] [Related]  

  • 19. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
    Pagidipati NJ; Lopes RD
    J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes.
    Cattadori G; Pantanetti P; Ambrosio G
    Diabetes Res Clin Pract; 2019 Nov; 157():107835. PubMed ID: 31479706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.